Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic microbiological laboratories  by Hrabák, J. et al.
Detection of carbapenemases in Enterobacteriaceae: a challenge for
diagnostic microbiological laboratories
J. Hrabak, E. Chudackova and C. C. Papagiannitsis
Department of Microbiology, Faculty of Medicine and University Hospital in Plzen, Charles University in Prague, Plzen, Czech Republic
Abstract
Carbapenemase-producing bacteria have now spread all over the world. Infections caused by those bacteria are difﬁcult to treat. Therefore,
there is an urgent need for accurate and fast detection of carbapenemases in diagnostic laboratories. In this review, we summarize screening
methods for suspected isolates, direct assays for conﬁrmation of carbapenemase activity (e.g. the Carba NP test and matrix-assisted laser
desorption ionization time-of-ﬂight mass spectrometry carbapenem hydrolysis assay), inhibitor-based methods for carbapenemase
classiﬁcation, and molecular-genetic techniques for precise identiﬁcation of carbapenemase genes. We also propose a workﬂow for
carbapenemase identiﬁcation in diagnostic laboratories.
Keywords: b-Lactamase, Carba NP, carbapenemase, detection, Enterobacteriaceae, MALDI-TOF MS
Article published online: 11 May 2014
Clin Microbiol Infect 2014; 20: 839–853
Corresponding author: J. Hrabak, Department of Microbiology,
Faculty of Medicine and University Hospital in Plzen, Alej Svobody 80,
304 60 Plzen, Czech Republic
E-mail: Jaroslav.Hrabak@lfp.cuni.cz
Introduction
Progress in human medicine, especially in surgery, transplan-
tology, neonatology, haemato-oncology, and intensive medi-
cine, has been followed by prolonged hospitalization, and
excessive and long-term antibiotic treatment of patients
enfeebled by immunodeﬁciencies and invasive procedures. In
the environment of intensive-care units (ICUs), incubators, and
haemato-oncology cleanrooms, nosocomial infections have
become a serious problem, with decisive effects on mortality
rates and treatment outcomes [1]. In an international study on
the prevalence and outcomes of infections in ICUs with >1200
participants, 51% of patients were considered to be infected,
and the mortality rate of the infected patients was at least
twice as high as that of the uninfected patients [2]. Members of
the Enterobacteriaceae are among the major causative agents of
nosocomial infections [3].
At the beginning of a new millennium, multiresistant
enterobacteria producing extended-spectrum b-lactamases
(ESBLs) and acquired AmpC-type cephalosporinases have
already spread worldwide, mainly as nosocomial pathogens,
but also in the community [4]. It is difﬁcult to control all of the
factors responsible for the spread of carbapenemase-produc-
ing bacteria. However, the high consumption of carbapenem
antibiotics connected with this epidemic situation has been
one of the main reasons for their rapid spread. Additionally,
other factors may include co-selection by other antibiotics
(e.g. cephalosporins), spread of those bacteria in community,
uncontrolled spread in the hospital environment, owing to
undiagnosed carriers, and other, still unknown, factors [5,6].
Carbapenemase-producing Enterobacteriaceae (CPE) have
already been detected all over the globe, with a marked
endemicity according to enzyme type. In Europe, the most
critical situations have been reported in Greece, with 60.5%
carbapenem-resistant Klebsiella pneumoniae (a total of 1460
isolates), and in Italy, with 28.8% carbapenem-resistant
K. pneumoniae (a total of 841 isolates), recovered from blood
within the EARS-Net project in 2012 (EARS Report 2012). The
prevalence of CPE in the community is not well known, and it
is most probably diverse, as for ESBL-producing Escherichia coli
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(3–5% in France; >80% in India) [5]. Besides medical settings,
carbapenemase-producing bacteria have been detected in
environmental samples, especially from sewage water, as well
as in veterinary and wildlife samples [7–10].
Enterobacteriaceae are known as some of the most common
pathogens causing both community-acquired and hospi-
tal-acquired infections, including infections of the urinary and
gastrointestinal tracts, pneumonia, peritonitis, meningitis, sep-
sis, and medical device-associated infections. The infections
caused by CPE are associated with signiﬁcant mortality. The
mortality rates revealed in small clinical studies ranged from
22% to 72%. [11,12]. The reasons for this are most probably
multifactorial, including underlying diseases, delays in the
initiation of effective therapy, and the lack of effective
antimicrobials [13].
The production of acquired carbapenemases makes the
choice of antibiotic treatment of infections caused by
Gram-negative bacteria very limited. The horizontal transmis-
sion of carbapenamase genes mediated by mobile genetic
elements carrying additional resistance elements, which confer
resistance to various groups of antibiotics, results in multidrug
resistance, including bacteria resistant to all available antibiot-
ics [14]. In vitro susceptibility to colistin, tigecycline and
aminoglycosides is mostly preserved, but the impact of these
antibiotics in vivo is still uncertain and the mortality rates
remain high, despite treatment according to the results of
susceptibility testing [15]. Some studies have suggested that
combination therapy could be associated with a better
outcome than monotherapy [15,16]. However, there is still
not an equal substitute for carbapenem antibiotics in the
treatment of severe infections caused by multiresistant
Gram-negative bacteria.
As a part of the human intestinal ﬂora, Enterobacteriaceae
are easily spread (hand carriage, and contaminated food and
water) and difﬁcult to eliminate, especially in countries with
low levels of hygiene. An alarming example has been the
successful worldwide spread of E. coli ST131 producing
CTX-M-15 [4,17]. High rates of, mainly, community-onset
extraintestinal infections caused by this successful clone have
been detected in Europe, North America, Japan, and Korea.
Even higher rates are estimated from limited data in Asia, the
Middle East, and Africa. The same clone has been reported in
companion animals, non-companion animals, and foods [17].
The epidemic situation regarding CPE will probably develop in
the same way as for ESBL producers. The only hope is an
efﬁcient infection control strategy applied in as many countries
as possible.
Data from Israel have shown that nosocomial infections
caused by carbapenem-resistant Enterobacteriaceae can be
controlled by strict epidemiological intervention. Acquisition
of CPE declined in acute care from a monthly high of
55.5 cases per 100 000 patient-days to an annual low of
4.8 cases per 100 000 patient-days [18]. However, for such a
successful intervention, there is an urgent need for diagnostic
laboratories to introduce rapid and sensitive methodologies
for the detection of carbapenemase producers.
Screening for carbapenemase producers
Susceptibility of CPE and indicator antibiotics
Proper selection of suspicious isolates with reduced suscep-
tibility to indicator antibiotics (e.g. carbapenems) is crucial for
the identiﬁcation of carbapenemase-producing isolates. These
isolates should be further examined for conﬁrmation of
carbapenemase production. However, some carbapenem-
ase-producing bacteria might show lower MICs for carbapen-
ems than the clinical breakpoints proposed by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST).
MIC distributions are available from http://mic.eucast.org/
(accessed 28 December 2013) and the CLSI [19]. Therefore,
previous studies suggested that enterobacterial isolates show-
ing even a small reduction in susceptibility to carbapenems
should be further examined for carbapenemase production
[20].
Recently, the EUCAST subcommittee for detection of
resistance mechanisms and speciﬁc resistance of clinical and/or
epidemiological importance published a recommendation for
detection of CPE (EUCAST guidelines for detection of
resistance mechanisms and speciﬁc resistances of clinical and/
or epidemiological importance: http://www.eucast.org/ﬁlead-
min/src/media/PDFs/EUCAST_ﬁles/Consultation/EUCAST_
guidelines_detection_of_resistance_mechanisms_121222.pdf
(accessed 28 December 2013)). Screening cut-off values were
proposed for meropenem, imipenem, and ertapenem
(Table 1). Meropenem was additionally proposed as the
indicator antibiotic with the best balance of sensitivity and
speciﬁcity, but, for bacteria producing OXA-48-type b-lacta-
mases, temocillin was proposed as an indicator antibiotic with
high sensitivity, as those isolates showed very high MICs for
this antibiotic (≥256 mg/L) [21]. However, the speciﬁcity of
this feature remains to be more extensively evaluated [22].
Huang et al. [23] recently published a precise analysis of
1354 enterobacterial isolates, including 435 conﬁrmed carba-
penemase producers. Most of the analysed CPE possessed
class D OXA-48-type b-lactamases. On the basis of their data,
it can be hypothesized that the current cut-off values for
carbapenems proposed by the EUCAST were not able to
identify a signiﬁcant number of OXA-48 producers. In
geographical areas with a high prevalence of CPE, including
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OXA-48 producers, the use of temocillin disks (30 lg) and
piperacillin–tazobactam disks (100/10 lg) can signiﬁcantly
increase the sensitivity of screening procedures. New cut-offs
were proposed for those antibiotics (temocillin, <12 mm;
piperacillin–tazobactam, <16 mm) [23]. The use of the com-
bination of modiﬁed zone diameter cut-offs can exclude the
presence of any carbapenemases that could have been missed
with other selection criteria, and avoid unnecessary additional
testing for conﬁrmation of CPE [23].
Recently, Hartl et al. [24] proposed the determination of
MICs for temocillin (cut-off of ≥128 mg/L) combined with the
meropenem double-disk synergy test (DDST) as an algorithm
that could be introduced into diagnostic laboratories for the
identiﬁcation of carbapenemase production and differentiation
of Ambler classes in CPE.
Another screening carbapenem antibiotic, faropenem, was
proposed by Day et al. [25]. They tested 166 enterobacterial
strains producing various carbapenemases, and 82 non-carb-
apenemase producers. In most carbapenemase-producing
strains, no inhibition zones (i.e. zone diameter of 6 mm)
around the faropenem disk (10 lg) were observed. For
OXA-48 producers, inhibition zone diameters ranged from
6 mm to 12 mm. For all but one OXA-48 producer with an
inhibition zone of >6 mm, large numbers of colonies growing
up to the disk were observed. MICs of faropenem were
≥64 mg/L for all VIM-producing, IMP-producing and KPC-pro-
ducing strains, and 99% of NDM-1-producing strains. Farope-
nem MICs of OXA-48-producing strains ranged from 2 mg/L
to 32 mg/L. Similar results were obtained in ﬁve of 82
non-carbapenemase-producing Enterobacteriaceae with the disk
diffusion test. Four non-carbapenemase-producing strains had
MICs of >32 mg/L. The authors of this study hypothesized that
the faropenem disk diffusion test can be used as a sensitive
(99%) and speciﬁc (94%) screen for carbapenemase-producing
bacteria. Similar results (sensitivity of 98% and speciﬁcity of
87%) were conﬁrmed in the collection of isolates referred to a
UK reference laboratory. However, further validation of this
test should be performed.
Finding speciﬁc and sensitive indicator antibiotics that are
similar to cefoxitin for screening of methicillin-resistant
Staphylococcus aureus is a challenge for the diagnosis of
carbapenemase-producing bacteria. Because of the great
diversity of carbapenemases, with different biochemical prop-
erties, solution of this problem will be difﬁcult.
Screening cultivation media
The recommended samples for the screening of CPE are faecal
or rectal swabs, as gastrointestinal carriers represent the most
important potential source of cross-transmission in the
healthcare setting. All patients at risk (e.g. patients repatriated
from a foreign country or from a healthcare setting with a high
prevalence of CPE, patients in ICUs, transplant patients, and
immunocompromised patients) should be screened. The
patients should be kept in strict isolation until a negative
result is announced (at least 24–48 h) [5].
An ideal screening medium should be designed to detect all
classes of carbapenemase with a high sensitivity and sufﬁcient
speciﬁcity to obtain a reliable answer to the question of
whether a patient is or is not colonized by CPE as soon as
possible. Attention should be given to the price and the
screening frequency in each laboratory, as well as to the
increasing number of tested samples. Faster results could be
achieved with an agar-based chromogenic medium for direct
plating, without any necessary enrichment in liquid medium.
However, no appropriate medium is available at this moment.
Several commercial media have been tested on molecularly
well-characterized carbapenemase-producing strains and on
clinical samples. Adler et al. [26] have compared three
agar-based screening media for the direct detection of CPE
from rectal swabs: CHROMagar-KPC (Hy-Labs, Rehovot,
Israel), MacConkey agar supplemented with imipenem at
1 mg/L, and MacConkey plates with imipenem, meropenem
and ertapenem disks. The highest sensitivity (85%) and
speciﬁcity (94.3%) have been observed for MacConkey agar
supplemented with imipenem. However, only KPC producers
were detected in this survey.
In a comparative study, Nordmann et al. suggested that a
culture medium designed for screening of ESBL producers
(ChromID ESBL; bioMerieux, La-Balme-Les-Grotte, France)
could achieve higher sensitivity than a medium designed to
TABLE 1. Clinical breakpoints of
selected carbapenems proposed for
Enterobacteriaceae, and European
Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) pro-
posals for screening cut-offs for the
detection of carbapenemases
Clinical breakpoints (susceptible category) Screening cut-off
MIC (mg/L)
Disk diffusion
inhibition zone
diameter (mm)
MIC (mg/L)
Disk diffusion
inhibition zone
diameter (mm)EUCAST CLSI EUCAST CLSI
Ertapenem ≤0.5 ≤0.25 ≥25 ≥23 >0.125 <25
Imipenem ≤2 ≤1 ≥22 ≥23 >1 <23
Meropenem ≤2 ≤1 ≥22 ≥23 >0.125 <25
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select carbapenemase producers (CHROMagar KPC; CHRO-
Magar, Paris, France) [27,28]. However, low speciﬁcity caused
by co-detection of ESBL producers necessitates further
diagnostic tests before reporting of the deﬁnitive results.
A prototype chromogenic screening medium, ChromID
CARBA (bioMerieux), designed for the detection of CPE, was
tested against a group of 200 rectal swabs (133 presumptive
CPE; 92 conﬁrmed by phenotypic and genotypic tests) [29].
Direct plating onto ChromID CARBA medium was performed
in parallel with four other screening methods: (i) overnight
selective enrichment in 5 mL of tryptic soy broth with a 10-lg
ertapenem disk, followed by plating onto MacConkey agar; (ii)
short, selective enrichment in 9 mL of brain–heart infusion
broth with a 10-lg ertapenem disk, followed by plating onto
ChromID ESBL medium; (iii) direct plating onto ChromID
ESBL; and (iv) direct plating onto MacConkey agar supple-
mented with meropenem (1 mg/L). Direct plating on Chro-
mID CARBA showed higher sensitivity (92.4%) and speciﬁcity
(96.9%) than the rest of the methods.
None of the media mentioned above is suitable for
detecting producers of OXA-48-type carbapenemases,
because these strains are usually susceptible to cephalosporins,
and often show low-level resistance to carbapenems. An
overnight culture in broth, supplemented with ertapenem,
followed by cultivation on Drigalski agar medium, with
ertapenem and imipenem E-tests, was suggested as the
preferable methodology for the selection of OXA-48 produc-
ers by Ruppe et al. [30,31].
Singh et al. compared the efﬁciency of direct plating on two
different selective media (CHROMagar ESBL and vancomycin,
amphotericin B, ceftazidime and clindamycin plates) with a
real-time PCR assay for blaKPC genes after a cultivation step in
an enrichment broth for the selection of KPC producers from
rectal specimens. PCR demonstrated higher sensitivity (97.0%)
than culture with selective screening media (77.3%), with a
signiﬁcantly shorter turn-around time (24 h for the PCR-based
method vs. 64–72 h for culture) [32]. These results indicate
that PCR-based screening of CPE is the most effective
procedure. This conclusion, however, does not take into
account the high cost of PCR assays and the numerous samples
examined, which force microbiologists to develop a screening
medium for direct plating with comparable sensitivity. The
speciﬁcity of CPE detection with current screening media,
usually mentioned in some publications, depends greatly on the
collection of isolates used for the validation, and cannot be
extrapolated to regions with different epidemiological situa-
tions.
Recently, a novel screening medium was developed by
Nordmann et al. [33]. This medium showed very high sensi-
tivity (96.5%) in also detecting OXA-48-producing strains [34].
This medium is based on Drigalski agar supplemented with
ertapenem, zinc sulphate, and cloxacillin. SUPERCARBA
medium has superior sensitivity to other, commercially
available, media (CHROMagar KPC and Brilliance CRE) [34].
Phenotypic tests
Numerous studies have described and evaluated the perfor-
mance of simple phenotypic tests for the speciﬁc detection of
carbapenemase-producing strains, mainly of K. pneumoniae and
E. coli.
Modiﬁed Hodge test
In the last two decades, detection of b-lactamase production
with a modiﬁcation of the disk diffusion test has been of
interest for many research groups. Three-dimensional tests for
the detection of extended-spectrum and AmpC b-lactamases
were described in 1990 and 2000 [35–37]. All of the described
methods were based on the application of a heavy bacterial
inoculum or a crude extract of tested isolates into a slit or a
cup cut in the agar, at different distances from the antibiotic
disks. The deformation of the inhibition zone in the vicinity of
the inoculated slit or cup cut was indicative of the presence of
ESBLs or AmpC-type b-lactamases. A similar technique was
developed in 1976 by Masuda et al. [38], and was later
modiﬁed by Marchiaro et al. and Pasteran et al. [39,40]. Disks
soaked with the tested culture or cell-free extract were placed
near the indicator antibiotic disks onto agar plates, which had
been previously inoculated with an E. coli susceptible strain.
Carbapenemase production was suggested by the growth of
the indicator E. coli cells around the disks loaded with the
tested isolates or crude extracts. However, all of the above
methods are labour-intensive, and they have not been widely
used in diagnostic laboratories.
One of the most extensively used methods is based on
techniques ﬁrst described by Ørstavik and Ødegaard in 1971
[41], and later by Hodge et al. in 1978 [42]. The latter method
was used for the detection of penicillinase production in
S. aureus, Neisseria gonorrhoeae, and other microorganisms.
The plate was inoculated with a susceptible strain of S. aureus,
a penicillin disk (10 U) was placed in the centre of the plate,
and tested isolates were streaked outward from the disk.
b-Lactamase production was veriﬁed as a distortion of the
inhibition zone.
In 2001, Lee et al. [43] published a modiﬁcation of the
Hodge test. The modiﬁed Hodge test was used for the
detection of carbapenemase production in Pseudomonas spe-
cies and Acinetobacter species [43]. In the modiﬁed Hodge test,
penicillin-susceptible S. aureus was replaced with E. coli
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ATCC 25922, and a 10-U penicillin disk with a 10-lg
imipenem disk. Two years later, the same authors published
an evaluation of their test [44]. In the latter study, Lee et al.
showed that the sensitivity of the modiﬁed Hodge test for the
differentiation of metallo-b-lactamase (MBL) producers could
be improved by the addition of zinc sulphate to an imipenem
disk or to Mueller–Hinton agar.
Although the modiﬁed Hodge test is simple and cheap, a
high frequency of false-positive results has been observed,
especially in carbapenem-resistant Enterobacteriaceae that
produce ESBLs (e.g. CTX-M type) or AmpC b-lactamases
with porin deﬁciency in their cell walls [45,46]. Pasteran et al.
[40,47] proposed further modiﬁcations of the modiﬁed Hodge
test to exclude false-positive results in some AmpC and ESBL
producers. Also, the modiﬁed Hodge test failed to detect
carbapenemase production in some isolates. Performance of
the modiﬁed Hodge test with MacConkey agar and ertapenem
disks gave better sensitivity for MBL producers, owing to
enhanced release of b-lactamases from cells [48]. However,
Girlich et al. [49] observed very low sensitivity for the latter
modiﬁcation, especially in NDM-1-producing bacteria.
False-negative results were minimized after the addition of
zinc sulphate to Mueller–Hinton agar; nevertheless, the test
still remained negative for some NDM producers (the
sensitivity increased from 77.4% to 94.0%).
Two recent studies reported different sensitivities and
speciﬁcities for the modiﬁed Hodge test [50,51]. In the ﬁrst
study, Cury et al. [50] found an excellent negative predictive
value (100%). Unfortunately, the study was limited to
KPC-producing Enterobacteriacea only. The authors also found
a high frequency of inconclusive results. In contrast, Doyle
et al. [51] described only 58% sensitivity and 93% speciﬁcity.
A disadvantage is that the assay is time-consuming, as it
requires 24–48 h for the ﬁrst results after isolation of a
suspected carbapenamase-producing strain, and cannot distin-
guish the carbapenemase type.
Despite the problems with the interpretation of the
modiﬁed Hodge test and the relatively high rates of
false-positive and false-negative results with some isolates,
the CLSI proposed this test for conﬁrmation of putative
carbapenemase producers [52]. On the basis of the results
reviewed above, however, the modiﬁed Hodge test should not
be used for ﬁnal conﬁrmation of carbapenemase production.
Detection of MBLs based on inhibition by chelating agents
Phenotypic detection of MBL producers is based on the
speciﬁc inhibition of MBLs by chelating agents. Several tests
relying on the synergy between MBL inhibitors, most com-
monly EDTA [43,53], and an oxyimino-cephalosporin or a
carbapenem, have been developed. Additionally, various tests
utilizing other chelating agents, such as dipicolinic acid (DPA)
[54], 1,10-phenanthroline [55], and thiol compounds (2-mer-
captopropionic acid and sodium mercaptoacetic acid) [44,56],
or the use of a combination of chelators (e.g. EDTA plus
2-mercaptopropionic acid) [57], have been proposed. These
compounds inactivate MBLs that act against b-lactams, by
depriving them of hydrolytically essential Zn+ divalent cations.
The DDST and the combined disk test (CDT) are the most
commonly used formats of MBL detection assays. The DDST
uses a b-lactam disk placed closed to a disk with a given
amount of an MBL inhibitor (most commonly EDTA). The
formation of a synergy pattern is indicative of MBL production.
Alternatively, in the CDT variant, the b-lactam disk is
potentiated with an inhibitor, and the diameter of its inhibition
zone is then compared with that of the b-lactam disk alone. An
increase in the inhibition zone diameter above a predeﬁned
cut-off value indicates MBL activity. Both formats of MBL
detection test show high sensitivity even with isolates with low
carbapenem resistance levels [20]. However, in the case of the
DDST, the interpretation of this test is subjective and cannot
be quantiﬁed.
Investigators have proposed various techniques for EDTA-
based detection tests, mainly in the DDST format. In the ﬁrst
study, presented by Arakawa et al. [56], a ceftazidime (30 lg)
disk was placed near a ﬁlter disk with a centre-to-centre
distance of 10–25 mm. To the ﬁlter disk, 5 lL of a 0.1 M
EDTA solution was added. EDTA expanded the growth-inhib-
itory zone between the two disks, but its appearance and
reproducibility were relatively poor, even when a 0.5 M EDTA
solution was added to the ﬁlter disk. In a study presented
1 year later, the use of an imipenem (10 lg) disk and an EDTA
(c. 1.5 mg) disk at a distance of 10 mm (edge to edge) was
proposed [43]. A 1.5-mg EDTA disk was prepared by adding
10 lL of a 0.5 M EDTA solution (pH 8.0) to a blank ﬁlter
paper disk. Lee et al. found that the sensitivity and speciﬁcity
for the EDTA-based DDST test were both 100% as compared
with the imipenem hydrolysis assay. In a later study, Lee et al.
showed that addition of sodium mercaptoacetic acid (c. 2 mg)
to an EDTA disk improved detection and elimination of a
non-speciﬁc inhibition zone for both Pseudomonas aeruginosa
and acinetobacters [44]. In that study, however, disks
containing a smaller concentration of EDTA (750 lg) were
used, because they alone did not produce the undesirably large
inhibition zones. A CDT format of an EDTA-based detection
test was presented by Yong et al. in 2002 [53]. In the latter
test, the inhibition zones of imipenem (10 lg) and imipenem–
EDTA (0.750 lg) disks were compared. This method, using a
≥ 7-mm inhibition zone with the imipenem–EDTA disks,
differentiated all MBL-producing pseudomonads, and the
sensitivity and speciﬁcity for acinetobacters were 95.7% and
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91.0%, respectively. Recently, a group of experts from the
EUCAST and the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) published a recommenda-
tion for the detection of class A and B enzymes in Enterobac-
teriaceae. In the procedures recommended, the production of
class B enzymes is suspected when a difference of ≥5 mm in
the zone diameter is observed between meropenem (10 lg)
and meropenem plus EDTA (0.25 M) [58].
On the same principle, the E-test MBL strip (AB bioMerie-
ux, Paris, France) is one of the methods advocated for the
detection of MBL-producing isolates [20]. This method, which
uses imipenem and imipenem plus EDTA, is efﬁcient in
detecting MBL producers showing high carbapenem resistance
levels, but may fail to detect MBL-producing isolates with
low-level resistance to imipenem. Recently, novel E-test strips,
containing meropenem and meropenem plus EDTA, have been
credited with high sensitivity and speciﬁcity for the initial
characterization of MBL-producing Enterobacteriaceae [58].
The sensitivity of MBL detection methods was signiﬁcantly
increased if the growth media were supplemented with zinc
[49,59].
In general, MBL detection methods based on b-lactam–
chelator combinations perform well for K. pneumoniae and
E. coli, but they have not been systematically tested for other
enterobacterial species. Also, it must be pointed out that the
speciﬁcity of MBL detection methods might be impaired by the
effects of chelating agents, acting non-speciﬁcally and affecting
other processes [60–62]. Therefore, the results should be
cautiously interpreted, and conﬁrmed with a reference meth-
odology (carbapenem hydrolysis-based assays—see below).
Detection of KPCs based on inhibition by boronic acids
Phenotypic detection of KPC production is based on the
inhibitory effects of boronic acid and its derivatives, phenylbo-
ronic acid (PBA) and 3-aminophenylboronic acid (APBA).
Boronate derivatives that structurally resemble b-lactams have
long been used in probing the function of b-lactamases,
especially class C enzymes. In 2008, Pasteran et al. [63]
observed that boronates preferentially inhibit KPC-type
b-lactamases. This report was soon followed by studies
proposing the use of PBA combined with a carbapenem for
the identiﬁcation of KPC producers [64–66]. These studies
differed in the performance of boronate-based tests, and the
observed sensitivity and speciﬁcity. In the study performed by
Pasteran et al. [64], the DDST approach was found to work
well. However, so far, the CDT format has been used more
and has evaluated as being better. Of several indicator
b-lactams tested, either imipenem [64] or meropenem
[65,66] showed better sensitivity and speciﬁcity for the
identiﬁcation of isolates producing KPCs or any other
members of the class A carbapenemases. Also, different
cut-off values of zone diameter differences between carbape-
nem disks and carbapenem disks supplemented with PBA were
used. Pasteran et al. [64] proposed an increase of ≥4 mm in
the zone diameters of imipenem disks combined with PBA
over those for imipenem alone. In the study performed by Doi
et al. [65], a potentiation of ≥5 mm was observed for all
KPC-producing isolates when APBA was added to meropenem
disks. The use of a ≥7 mm cut-off for meropenem disks, with
and without 400 lg of PBA, was proved to be excellent for
identifying KPC-producing K. pneumoniae strains and differen-
tiating them from plasmidic AmpC-producing K. pneumoniae
and E. coli [66].
Apart from the disk diffusion approaches, a method in which
MICs of carbapenems were determined in the absence and in
the presence of 0.3 mg/mL APBA has been developed [64]. A
≥3-fold reduction in the MICs of imipenem has been proposed
as the cut-off for differentiating class A carbapenemase-pro-
ducing bacteria from non-carbapenemase-producing bacteria
with maximum sensitivity and speciﬁcity (both being 100%).
As with the MBL detection tests, experience with boro-
nate-based detection of KPC producers is limited, mainly, to
K. pneumoniae. In general, boronate-based tests show high
sensitivity in the detection of KPC producers. However,
speciﬁcity problems may arise with isolates showing reduced
susceptibility to carbapenems, owing to high-level expression
of AmpC-type b-lactamases (cephalosporinases) and porin
defﬁciency [64]. This could be explained by the observed
signiﬁcant inhibition of AmpC enzymes by boronic acids [67].
The problem can be partly overcome by the simultaneous use
of cloxacillin, which preferentially inhibits cephalosporinases
[68].
Differentiation of MBLs and/or KPCs based on combined disk
methods
Recently, the emergence of K. pneumoniae strains co-produc-
ing KPCs and VIM b-lactamases in Greek hospitals was
documented [69–71]. Hospital infections caused by K. pneu-
moniae co-producing KPCs and MBLs have also been described
in other regions, such as Germany, Italy, China, and Colombia
[72–76]. The spread of double carbapenemase producers has
compromised the performance of the chelator-based and
boronate-based tests described above. Previous studies have
shown that double carbapenemase producers may appear to
be negative for one or even both carbapenemases [69,70,74].
In 2010, Tsakris et al. [77] described an assay for the
phenotypic differentiation of MBLs and class A carbapenemas-
es in enterobacterial isolates. The described assay used four
disks: meropenem, meropenem plus PBA, meropenem plus
EDTA, and meropenem plus PBA and EDTA. The method
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failed to detect one of the double carbapenemase producers
tested, and it misclassiﬁed two ESBL and AmpC producers as
KPC producers.
Recently, Miriagou et al. presented two modiﬁcations of the
KPC/MBL kit (ROSCO Diagnostica, Taastrup, Denmark)
(Giakkoupi et al., 22nd ECCMID, 2012, Abstract P1721). The
KPC/MBL kit contains four tablets: meropenem (10 lg),
meropenem plus APBA (600 lg), meropenem plus DPA
(1000 lg), and meropenem plus cloxacillin (75 lg) (www.
rosco.dk) [68,79]. In the ﬁrst modiﬁcation (Method A), an
additional tablet containing meropenem plus APBA and EDTA
was included. The second modiﬁcation (Method B) differed
from the ﬁrst one only in that APBA was replaced with PBA
(400 lg). The performance of both modiﬁcations was com-
pared with that of the original KPC/MBL kit and the
phenotypic assay (Method C) described previously by Tsakris
et al. [77]. All four methods showed excellent speciﬁcity, and
performed well against single carbapenemase producers.
However, signiﬁcant problems were encountered with the
subset of double carbapenemase producers. The lowest
sensitivity was observed with the KPC/MBL kit, which missed
32 double carbapenemase producers. Methods A and C also
showed low sensitivity. The sensitivity was signiﬁcantly
improved for Method B, which failed to detect only one
double carbapenemase producer. Miriagou et al. [78] sug-
gested that the key changes explaining the observed high
diagnostic value of Method B were the inclusion of additional
combined tablets containing meropenem plus two inhibitors
(DPA for MBLs, and a boronic acid derivative for KPCs) and
the replacement of APBA with PBA. The algorithm used to
interpret the results of Method B, with some modiﬁcations, is
shown in Fig. 1. The main limitation of that study is that all four
methods were tested against a single enterobacterial species,
K. pneumoniae.
None of the detection tests reviewed above is suitable for
the identiﬁcation of isolates producing acquired OXA-type
carbapenem-hydrolysing class D b-lactamases. The enzymatic
properties of OXA-type carbapenemases, which are not
inhibited by clavulanic acid, tazobactam, sulbactam, or any zinc
chelator, prevented the development of speciﬁc phenotypic
tests for their detection. High-level resistance to both
temocillin (MICs of >64 mg/L) and piperacillin–tazobactam in
Enterobacteriaceae showing reduced susceptibility or resistance
to at least one carbapenem may be predictive of production of
OXA-48 [21]. Regarding the proposed modiﬁcation
(Method B) of the KPC/MBL kit, Miriagou et al. [78] suggested
that isolates that are negative with both ‘double’ disks and the
‘triple’ disk must be further examined for other carbapenem
resistance mechanisms, most importantly OXA-48 production.
Deﬁnite conﬁrmation of such isolates requires molecular
techniques (e.g. PCR-based methods) for the precise identi-
ﬁcation of carbapenemase genes.
Molecular-genetic Techniques
Molecular techniques remain the reference standard for the
precise identiﬁcation of carbapenemase genes [5]. Most of
Screening cut-off *
Meropenem MIC ≥0.25
Synergy of Mem with DPA 
(≥5 mm)
MBL
Synergy of Mem with DPA+PBA 
(double inhibitor)
Synergy of Mem with PBA 
(≥4 mm)
No
synergy of Mem with 
cloxacillin (<5 mm)
Synergy of Mem with 
cloxacillin
(≥5 mm)
KPC AmpC
Synergy of Mem
with double inhibitor 
against PBA 
(≥4 mm)
Synergy of Mem
with double inhibitor 
against DPA 
(≥4 mm)
Synergy of Mem
with double inhibitor 
against DPA and PBA 
(≥4 mm)
KPC MBL
No
synergy of Mem with PBA 
(<4 mm)
No
synergy of Mem with DPA 
(<5 mm)
No
synergy of Mem
with double inhibitor against 
DPA and PBA 
(<4 mm)
OXA-48 KPC + MBL
Screening cut-off*
Temocillin MIC ≥128
FIG. 1. Algorithm proposed by Miriagou et al. [78] for interpretation of results obtained with the KPB/MBL conﬁrmation-based Method B. The
algorithm has been modiﬁed for the detection of OXA-48-type carbapenemases and the use of screening cut-offs proposed by the European
Committee on Antimicrobial Susceptibility Testing. *Ertapenem MIC ≥0.25 mg/L, imipenem MIC ≥2 mg/L or piperacillin–tazobactam (inhibition
zone of <16 mm) can also be used. DPA, dipicolinic acid; MBL, metallo-b-lactamase; PBA, phenylboronic acid.
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these techniques are based on PCR technology, and may be
followed by sequencing of the entire coding region if identi-
ﬁcation of the b-lactamase gene is required.
Also, hybridization techniques have been commonly used
for the identiﬁcation of carbapenemase genes in research
laboratories and reference centres. Combination of hybridiza-
tion techniques and Southern blotting is used to determine
whether the carbapenemase gene resides on a plasmid or is
chromosomal [80,81]. Additionally, some other laboratories
have used colony blot hybridizations to efﬁciently screen large
numbers of clinical isolates for the presence of carbapenemase
genes [80,82].
Currently, many clinical laboratories routinely use ‘in-house’
PCR-based methods in order to deal with the problems of
phenotypic detection methods and reduce the detection time.
A PCR technique performed directly on colonies can give
results within 4–6 h, with excellent sensitivity and speciﬁcity.
Additionally, as mentioned above, PCR-based methods allow
the detection of OXA-type carbapenemases. PCR-based
methods are either simplex [83] or multiplex PCR assays
[84–88]. Real-time assays, which further reduce the detection
time, have also been utilized [89–92]. Recently, microarray
technology was added to the list of molecular techniques, with
the aim of achieving the rapid and reliable detection of multiple
resistance determinants [93,94].
The main disadvantages of molecular techniques are their
cost and the requirement for trained microbiologists. An
additional issue with molecular methods is that the range of
resistance genes to be detected is predeﬁned. Thus, these
methods may not detect novel carbapenemase gene types.
PCR methods
When the presence of a carbapenemase is suspected, PCR is
the fastest way to determine which family of b-lactamase is
present. Numerous simplex PCR assays targeting a simple
carbapenemase type have been used in previous studies.
Queenan and Bush provided, in their review, a selection of
published primers that have been used in simplex PCR assays
to detect all of the families and subgroups known at this time
[83].
The increasing frequency of carbapenemase-producing
bacteria underlined the necessity of having tools available to
monitor the emergence and the spread of each family of
carbapenemase gene types. In 2007, Ellington et al. [84]
developed a multiplex PCR assay for the detection and
differentiation of the ﬁve different families, VIM, IMP, SPM,
GIM, and SIM, of acquired MBL genes in a single reaction. The
assay showed excellent performance, as it detected and
distinguished all of the reference strains, and found IMP and
VIM alleles in all isolates tested. Later, an update of the
described assay was presented by Poirel et al. [88]. The
updated assay, which consisted of three multiplex PCR
reactions, was aimed at additionally detecting the emerging
carbapenemase genes encoding the class A KPC, the class B
NDM-1, and the class D OXA-48, as well as the recently
identiﬁed genes encoding DIM-1, BIC-1, and AIM-1.
Following those reports, a set of six multiplex PCRs and one
simplex PCR for the rapid detection of the most widespread
b-lactamase genes encoding the OXA-1-like broad-spectrum
b-lactamases, ESBLs, plasmid-mediated AmpC b-lactamases
and class A, B and D carbapenemases was created by a
research group from France [86]. However, no carbapenem-
ase genes were detected in the clinical isolates tested. In 2011,
an update of the assay, described by Dallenne et al. [86], was
aimed at detecting the majority of genes encoding clinically
important b-lactamases causing third-generation cephalosporin
or carbapenem resistance. In the updated assay, Voets et al.
[87] developed seven multiplex PCRs for the detection of
plasmid-mediated AmpC b-lactamases (ACC, ACT, DHA,
CMY, FOX, LAT, MIR, and MOX), metallo-carbapenemases
(GIM, NDM, SIM, and SPM), serine carbapenemases (IMI, SME,
and NMC-A) and OXA b-lactamases (OXA groups 23, 24, 48,
1, 2, 51, 4, and 58), and they used four multiplex PCRs of
Dallenne et al. for the detection of genes encoding the
CTX-M, SHV, GES, VEB, PER, KPC, VIM and IMP b-lactamase
families. All of the multiplex PCRs were evaluated for
performance in a single ampliﬁcation protocol.
In 2010, Endimiani et al. presented a PCR-based method for
the detection and identiﬁcation of blaKPC genes among
Enterobacteriaceae [95]. However, that protocol makes use of
PCR/electrospray ionization–mass spectrometry (MS) tech-
nology, a promising genotyping system that has high multi-
plexing capacity and can be used for detecting different genes
in a single strain. This system can also detect single-nucleotide
polymorphisms, including mutations corresponding to changes
in amino acids. In the described study, all blaKPC-2-possessing
and blaKPC-3-possessing strains were correctly reported.
Additionally, all tested strains were correctly deﬁned at the
species level.
Apart from the ‘in-house’ assays, there are also commer-
cially available kits based on PCR and hybridization, e.g.
Hyplex MBL ID (BAG Health Care, Lich, Germany) for the
detection of blaVIM(1–13) and blaIMP(1–22), and Hyplex
CarbIxa ID (BAG Health Care) for the detection of blaOXA
carbapenemase genes. This methodology allows the detection
of carbapenemase-encoding genes from clinical samples (19th
ECCMID, 2009, Abstract P1054); however, its diagnostic
usefulness has to be further assessed in multicentre studies
that also include settings with a low prevalence of carbape-
nemase producers.
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Real-time PCR methods
Several multiplex real-time PCR methods, which further
reduce the detection time for carbapenemase genes, were
developed by research groups at the same time. Real-time
PCR methods can be followed by a melting curve step, allowing
the accurate differentiation of carbapenemase gene variants. In
2007, Mendes et al. [90] described the ﬁrst multiplex real-time
PCR assay for the detection of genes encoding MBL-type
enzymes (IMP and VIM types, SPM-1, SIM-1, and GIM-1)
identiﬁed up to that point. The MBL identiﬁcation was based
on the characteristic amplicon melting peak. In a study
published a few months later, the speciﬁc detection of blaVIM
and blaIMP genes in Gram-negative bacteria was achieved in
<1 h with a real-time PCR assay [89]. The authors showed that
melting curve analysis of the real-time PCR products clearly
differentiated the genes into four groups: (i) blaVIM-1-like; (ii)
blaVIM-2-like; (iii) blaIMP-1-like; and (iv) blaIMP-2-like.
In 2011, Chen et al. [91] developed a multiplex real-time
PCR scheme that could identify blaKPC gene variants. In
contrast to other PCR-based methods for the detection of
blaKPC genes, such as two real-time PCR assays [97,98] and a
method that uses PCR/electrospray ionization–MS [95], the
described protocol made use of the technology of molecular
beacon probes, which are able to detect the presence of
single-nucleotide polymorphisms. Thus, the described real-
time PCR could distinguish between different blaKPC variants
[91], and therefore provides information of both epidemio-
logical and evolutionary signiﬁcance. Later, Chen et al. [99],
using the technology of molecular beacon probes, designed a
multiplex real-time PCR assay capable of identifying both the
epidemic K. pneumoniae ST258 clone and blaKPC carbapenem-
ase genes in a single reaction. That assay showed excellent
sensitivity (100%) and speciﬁcity (100%), and seemed to be a
useful tool for screening of K. pneumoniae isolates and
surveillance of the epidemic ST258 clone in both community
and healthcare settings. Although the initial cost of investment
for the molecular beacons is signiﬁcant, it is offset by the
reduced requirements for template quality, reaction volume,
and time [100].
Recently, Monteiro et al. [92] developed a single multiplex
real-time PCR assay for the identiﬁcation of the most common
types of serine carbapenemase (KPC, GES, and OXA-48) and
metallo-carbapenemase (IMP, VIM, and NDM), already
described in enterobacterial isolates, using high-resolution
melting curves. The entire assay, including DNA extraction,
sample preparation, a multiplex PCR run, and analysis of
results, was performed in 3 h. In the two studies that followed:
(i) the performance of a real-time PCR for identiﬁcation of
blaVIM-type and blaKPC carbapenemases in an ultrarapid single
reaction was compared with the performance of other
PCR-based methods [101]; and (ii) a multiplex real-time PCR
assay for the detection of OXA-48, VIM, IMP, NDM and KPC
carbapenemase genes was evaluated in a multicentre study
[102].
Both the sensitivity and the speciﬁcity of all of the real-time
protocols presented above were 100%. These results indicate
that real-time PCR assays are robust, reliable and rapid
protocols for the detection of the most prevalent carbape-
nemase genes. Therefore, molecular methods should be used
for screening for the presence of the carbapenemase genes, so
that their epidemiological spread can be monitored.
Microarrays
DNA hybridization techniques in a microarray format allow
the simultaneous detection of many sequences. In 2010,
Ulyashova et al. [103] developed a microarray able to identify
KPC, OXA, IMP, SPM, VIM, SIM and GIM carbapenemases.
Commercially available microarrays for the detection of ESBLs
and carbapenemases have been recently validated [93,104].
This method provides excellent sensitivity and speciﬁcity.
Carbapenemases and other b-lactamases can be also detected
directly from blood cultures. However, sensitivity can be
inﬂuenced by the method used for DNA extraction.
Except for blood cultures, microararrays have not yet been
validated for the detection of b-lactamases from clinical
specimens. Their labour-intensive nature and relatively high
cost still prevent them from becoming routine for the
detection of carbapenemases in diagnostic laboratories.
Despite this, microarrays may provide useful data for epide-
miological typing of the isolates.
Direct Methods for Detection of
Carbapenemase Activity
In contrast to molecular-genetic techniques, which are only
able to detect genes that are already known, direct detection
of carbapenemase activity is also able to detect novel
carbapenemases. Therefore, these methods should be available
as reference standard methods for the detection of carbape-
nemase activity in routine diagnostic laboratories.
Colorimetric assays
Some of the simplest and cheapest methods for the detection
of b-lactamases are colorimetric assays that can detect
hydrolysis of the amide bonds of b-lactams according to
colour changes. Speciﬁc tests use a chromogenic b-lactam (e.g.
nitroceﬁn) that changes colour after being hydrolysed
[105,106]. Non-speciﬁc tests are based on non-speciﬁc
interactions with hydrolysed b-lactam molecules or on the
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detection of pH changes. A well-known non-speciﬁc test is the
starch–iodine assay [105–107]. After hydrolysis of the indica-
tor b-lactam, the colour of the reaction mixture or plate
around colonies of b-lactamase producers changes from dark
blue to colourless. For the detection of b-lactamase-producing
S. aureus, Haemophilus inﬂuenzae, and other bacteria, a phenol
red-based method has been developed. b-Lactamase produc-
tion is indicated as a change of colour from red to yellow
[106,108]. Recently, a phenol red-based method was modiﬁed
for the detection of carbapenemases in Enterobacteriaceae and
P. aeruginosa, known as the Carba NP test [22,109]. In this
test, a bacterial culture is mixed with lysis solution. After lysis,
the cell-free supernatant is mixed with a solution of phenol
red, zinc sulphate, and imipenem. In carbapenemase-producing
bacteria, the colour of the reaction changes from red to yellow
or to light red. This method also allows the preliminary
identiﬁcation of carbapenemase type (class A, B, or D) based
on the inhibition proﬁle with tazobactam and EDTA [109].
In 2013, Tijet et al. [111] published another validation of the
Carba NP test performed on a collection of 244 enterobac-
terial and P. aeruginosa isolates. They reported 100% speciﬁcity
of the test. However, the sensitivity (72.5%) was lower than
the 100% for Enterobacteriaceae and 94.4% for P. aeruginosa
reported originally [22,109,110]. The test gave false-negative
results in some mucoid isolates and especially in OXA-48-pro-
ducing Enterobacteriaceae. The authors hypothesized that this
behaviour could be attributable to low expression of carba-
penemase. With a two-fold higher bacterial concentration, the
sensitivity increased to 80%.
Recently, Dortet et al. [112] validated the Carba NP test for
the detection of carbapenemase producers from blood
cultures. Although there is one more 3-h step for incubation
in brain–heart infusion in the procedure, this modiﬁcation can
reduce the time needed for carbapenemase identiﬁcation from
approximately 24 h to 3–5 h.
The Carba NP test is a reliable method for the detection of
carbapenemases, especially of Ambler classes A and B, with
superior speciﬁcity. Whether or not the test is reliable for the
detection of all OXA-48-type carbapenemase producers and
other bacteria with low production or inefﬁcient carbapene-
mases must be determined in multicentre studies.
MS
In 2011, the ﬁrst methods for the detection of carbapenemase
activity by the use of matrix-assisted laser desorption ioniza-
tion time-of-ﬂight mass spectrometry (MALDI-TOF MS) were
published. In those assays, fresh bacterial culture is mixed with
carbapenem solution (meropenem or ertapenem) [113,114].
After incubation at 35–37°C for 2–4 h, the reaction mixture is
centrifuged, and the supernatant is measured by MALDI-
TOF MS. In spectra, the carbapenem molecule, its sodium
salts, and degradation products in the case of carbapenemase
hydrolysis, are visible. This method allows the detection of real
hydrolysis, without false-positive results. Some
OXA-48-type-producing strains, however, can give false-neg-
ative results. In some slime-producing strains, measurement
can be complicated by interactions with polysaccharides. The
mass spectra of such strains are usually difﬁcult to interpret.
The MALDI-TOF MS carbapenem hydrolysis assay has been
modiﬁed and validated by other research groups [115–118].
Interestingly, this method gives superior results for the
detection of OXA-type carbapenemases (CHDL) in Acineto-
bacter baumannii [119].
Another modiﬁcation of the MS method was proposed by
Carvalhaes et al. [120]. This group used liquid chromatography
(LC)–MS for the detection of carbapenem molecules and their
degradation products in CHDL-producing, IMP-producing,
NDM-producing, VIM-producing, GIM-producing, KPC-pro-
ducing and GES-producing bacteria. Incubation of the reaction
mixture for 4 h increased both the sensitivity and speciﬁcity of
the method to 100%. Recently, similar results were obtained
by Carricajo et al. [121], using ultra-performance LC–tandem
MS. Unfortunately, the equipment required for LC–MS is not
currently available in most diagnostic laboratories, in contrast
to MALDI-TOF mass spectrometers.
MALDI-TOF MS has now been introduced into many
microbiological laboratories across Europe as an identiﬁcation
procedure for bacteria and fungi. Although the costs of the
measurement (identiﬁcation of bacteria and fungi) are low, the
equipment remains expensive for countries with a low
economic status. Recently, this technology was approved by
the US Food and Drug Administration. Therefore, the
MALDI-TOF MS carbapenem hydrolysis assay may become a
reliable tool for conﬁrmation of carbapenemase activity in
both routine and reference laboratories. Unfortunately, no
automatic software for the analysis of acquired spectra has yet
been available. Therefore, the users must have some experi-
ence with MS measurement, in contrast to MALDI-TOF MS
for microorganisms. Another multicentre validation of this
method is also needed.
Spectrophotometric assays
Spectrophotometric detection of carbapenem hydrolysis has
been proposed as a reference method for conﬁrmation of
carbapenemase activity [122]. Although this approach is
labour-intensive, it cannot be used routinely in diagnostic
laboratories. For the detection of carbapenemase activity,
bacterial crude extract, usually prepared by sonication, is
added to buffered carbapenem solution (imipenem), and
hydrolysis of the b-lactam ring is measured in UV spectra
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[123–125]. Bernabeu et al. [123] demonstrated the ability of
the imipenem hydrolysis spectrophotometric assay to detect a
broad range of carbapenemases (100% sensitivity), including
OXA-48-type class D enzymes Laraki et al. [125]. Only one
Enterobacter cloacae strain overexpressing intrinsic AmpC was
misidentiﬁed as a carbapenemase producer (98.5% speciﬁcity).
Workﬂow in Routine Diagnostic Laboratories
Because of the global spread of carbapenemase-producing
bacteria, it is necessary to introduce methods for their
detection into all clinical diagnostic laboratories. For this
purpose, we recommend a workﬂow, shown in Fig. 2, for
carbapenemase identiﬁcation.
During an outbreak, in regions with a known epidemiolog-
ical situation, PCR-based screening can be performed directly
from clinical material, and the results will be available to
hospital epidemiologists within a few hours. Simultaneously,
the samples should be cultivated on screening cultivation
media to obtain an isolate for further molecular-epidemiolog-
ical typing. For other screening purposes, a sample should be
ﬁrst cultivated on a proper selective cultivation medium.
Carbapenemase production must be conﬁrmed by direct
detection of carbapenem hydrolysis. Carbapenemase genes
can be identiﬁed by PCR ampliﬁcation or a microarray
technique. Before molecular testing, inhibition (e.g. EDTA or
boronic acid) and susceptibility (e.g. temocillin) proﬁles of the
isolate may provide helpful information for the selection of a
more targeted PCR-based technique. Apart from screening
samples, detection of carbapenemase production should be
performed in any enterobacterial isolate (Table 1) with a
suspicious susceptibility proﬁle (usually isolates with clinical
signiﬁcance).
Conclusion
New, reliable methods for the detection of carbapenemases
have now been developed (e.g. the Carba NP test and the
During an 
outbreak
For epidemiological
purpose
Suspected isolate
(Based on 
susceptibility test 
results)
Screening sample
(e.g., rectal swab)
Any clinical isolate 
subjected for 
susceptibility testing 
PCR detection of 
carbapenemase genes
(based on the knowledge of 
epidemiological situation)
Cultivation on proper 
selective cultivation 
media
Molecular detection of 
carbapenemase genes
(based on phenotypic tests and 
local epidemiological situation)
Direct detection of 
carbapenemase activity 
(e.g., Carba NP test, MALDI-
TOF MS carbapenem
hydrolysis assay)
Other typing methods 
(e.g., MLST, PFGE, plasmid 
analysis)
Inhibitor-based 
phenotypic tests
FIG. 2. Proposed workﬂow for the detection of carbapenemases in diagnostic laboratories. MALDI-TOF MS, matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry; MLST, multilocus sequence typing; PFGE, pulsed-ﬁeld gel electrophoresis.
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MALDI-TOF MS hydrolysis assay). All of the methods, how-
ever, need experienced laboratory personnel. Therefore, in
countries with a low prevalence of CPE, ﬁnal conﬁrmation of
carbapenemase production should be performed in reference
laboratories. For the improvement of CPE diagnosis, national
authorities or international institutions should provide: (i)
education to the diagnostic laboratory staff (e.g. interpretation
of test results); and (ii) external quality controls for the
evaluation of laboratories responsible for the diagnosis of CPE.
Research on diagnostic methods should be further focused on
interlaboratory/multicentre validation of the method, and the
development of new methods for direct detection of CPE
colonies on selective cultivation media.
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